Nanoviricides Stock News

NanoViricides Inc (NYSE: NNVC) has initiated a program to screen its library of broad-spectrum antiviral nanoviricides against human Adenovirus 41 Type F (hAd41-F), believed to be strongly associat

Photo Credit: Photo by CDC & Klara Kulikova This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Shingles infections have been steadily increasing in the United States over the past two decades, according to the Centers for Disease Control and Prevention (CDC). The COVID-19 pandemic may be making matters worse because so many adults who are experiencing long COVID, have lower immunity and a high risk of developing shingles - an itchy, painful, often blistery rash that can occur and spread, particularly in the elderly. The existing antiviral treatments are largely ineffective at controlling the disease’s progression, and none of the existing antivirals used to treat shingles actually cure the infection, so new antivirals that can cure Shingles are needed. NanoViricides, Inc. has been Developing Antiviral Skin Cream For Shingles NanoViricides Inc. (NYSE-AMERICAN: NNVC), a developmental stage biotech, reports that it had developed a lead drug candidate for shingles before the pandemic.

Photo credit: Marcelo Leal and Kate Hliznitsova on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. In January, the U.S. Food and Drug Administration (FDA) revoked its emergency use authorization (EUA) of two COVID-19 antibody treatments that had initially been granted emergency use authorization by the agency in November 2020. The announcement comes after a review of the latest data showed that neither antibody treatment is especially effective against Omicron, which now accounts for an estimated 99% of new cases . Monoclonal antibodies work by targeting the spike protein on a virus particle. With each variant, that spike protein is a little different. In Omicron’s case, it’s a lot different. A study in Nature found that the variant contains over 30 mutations in the spike protein. While that’s made it easier for tests to distinguish it from other variants, it’s also made it more resistant to both vaccines and antibody treatments.

NanoViricides press release (NNVC): FQ2 GAAP EPS of -$0.17.The Company reported that it had approximately $17.35M of cash, cash equivalents as of December 31, 2022. The Company…

NanoViricides Inc. (NNVC) shares closed today at 1.7% above its 52 week low of $2.86, giving the company a market cap of $33M. The stock is currently down 21.8% year-to-date, down 11.3% over the past 12 months, and down 88.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 41.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 1241.6% The company's stock price performance over the past 12 months lags the peer average by -526.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

NanoViricides Inc. (NNVC) shares closed today at 1.7% above its 52 week low of $2.86, giving the company a market cap of $33M. The stock is currently down 21.8% year-to-date, down 14.4% over the past 12 months, and down 88.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 40.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 3.7% lower than its 5-day moving average, 17.9% lower than its 20-day moving average, and 34.2% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 1468.5% The company's stock price performance over the past 12 months lags the peer average by -361.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

NanoViricides Inc. (NNVC) shares closed this week 6.7% lower than it did at the end of last week. The stock is currently down 14.2% year-to-date, down 2.4% over the past 12 months, and down 88.1% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.6%. Trading Activity Shares traded as high as $3.92 and as low as $2.97 this week.Trading volume this week was 48.2% lower than the 10-day average and 59.5% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -981.5% The company's stock price performance over the past 12 months lags the peer average by -128.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

NanoViricides (NYSEAMERICAN:NNVC) issued its earnings results on Monday. The company reported ($0.23) EPS for the quarter, missing the Zacks consensus estimate of ($0.20) by ($0.03), Fidelity Earnings reports. Shares of NNVC stock opened at $4.76 on Thursday. The stock has a market capitalization of $54.81 million, a price-to-earnings ratio of -5.88 and a beta of []

NanoViricides, Inc. (NYSEAMERICAN:NNVC) was the target of a large drop in short interest in October. As of October 29th, there was short interest totalling 494,500 shares, a drop of 36.4% from the October 14th total of 777,000 shares. Currently, 4.5% of the companys stock are short sold. Based on an average trading volume of 2,500,000 []

SHELTON, CT / ACCESSWIRE / November 16, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel n

  NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2 Shelton, Connecticut -- (November 15, 2021) - NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, announced today that it has developed oral gummies formulations of its Pan-Coronavir...

SHELTON, CT / ACCESSWIRE / November 15, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomed

SHELTON, CT / ACCESSWIRE / October 13, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 202

NanoViricides Inc. ( NNVC , Financial) is one of the emerging biotech companies that I have been following for a while now. Its stock price had more than doubled last month after a major update from t

Shares of NanoViricides Inc (NYSE: NNVC), a developer of antiviral therapies based on a novel nanomedicines technology, are higher Monday. What Happened: NanoViricides said its pan-Coronavirus COVID